GI Innovation지아이이노베이션
358570 · KOSDAQ · ₩358570 · 지아이이노베이션
- Market cap
- ₩461B
- Enterprise value
- ₩423B
- P/E
- —
- P/B
- 4.8×
- Dividend yield
- 0.0%
- ROE
- −40.5%
- Net margin
- −711.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−65.9% from the high
₩6,470Today: ₩7,040 – ₩7,340₩20,950
Returns
- 1W−11.4%
- 1M−16.8%
- 3M+2.4%
- 6M−56.9%
- YTD−59.5%
- 1Y−55.0%
- Volume today
- 183,832
- 0.7× the 20-day average
- Traded today
- ₩1.3B
- Listed shares
- 64,516,006
- EPS (12 months)
- −₩607
- Earnings yield −8.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 36 of 100 (50 is a normal day for this stock).
- MomentumWeak-19.5% over the last month; the price is below its 20-day average.
- News impactSome1 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Sep 22: sell ₩452M at the close (13.7% of 20-day average trading value)
On its 32 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 1.9% of trading value and pointed the same way 4 of 32 times.
- 2× KODEX KOSDAQ150 Leverage −₩431M
- -1× KODEX KOSDAQ150 Futures Inverse −₩11M
- 2× TIGER KOSDAQ150 Leverage −₩6.2M
- 2× RISE KOSDAQ150 Futures Leverage −₩2.4M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
GI Innovation stock overview
GI Innovation (지아이이노베이션, KRX: 358570) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotech developing next-generation immunotherapy drugs based on fusion proteins, with a platform (GI-SMART) for discovering and producing bispecific fusion proteins. Its shares closed at ₩7,140 on Oct 28, 2026, up 1.56% on the day, giving it a market value of ₩461B.
Key facts
- Market cap
- ₩461B
- Sector
- Biotech & Pharma
- Latest price change
- +1.56%
- As of
- Oct 28, 2026
- Main business
- The company is a Korean biotech developing next-generation immunotherapy drugs based on fusion proteins, with a platform (GI-SMART) for discovering and producing bispecific fusion proteins.
Quick answers about GI Innovation
- What does GI Innovation do?
- The company is a Korean biotech developing next-generation immunotherapy drugs based on fusion proteins, with a platform (GI-SMART) for discovering and producing bispecific fusion proteins. Its pipeline includes the immuno-oncology candidates GI-101/GI-102, the allergy treatment GI-301, and the metabolic immuno-oncology candidate GI-108, most of which are in clinical stages, and it earns revenue mainly by licensing drug candidates to global pharmaceutical partners in early development stages rather than selling marketed drugs. Its partners include Simcere Pharmaceutical in China, Yuhan Corporation for GI-301 outside Japan, and MSD for joint clinical work, with clinical trials conducted in Korea, the United States, and Australia.
- What is the market cap of GI Innovation?
- The market capitalisation of GI Innovation was ₩461B at the close on Oct 28, 2026.
- Who are the largest shareholders of GI Innovation?
- According to the latest official filings, the largest reported holders are Jang Myung-ho (6.57%, as of Oct 7, 2026); Samsung Asset Management (5.04%, as of Aug 20, 2026); National Pension Service (4.07%, as of Dec 31, 2025).
- When is the next earnings report from GI Innovation?
- Korean companies rarely announce results dates in advance. Based on when GI Innovation filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own GI Innovation?
- Yes. The National Pension Service held 4.07% of GI Innovation shares as of Dec 31, 2025.
Company profile
The company is a Korean biotech developing next-generation immunotherapy drugs based on fusion proteins, with a platform (GI-SMART) for discovering and producing bispecific fusion proteins. Its pipeline includes the immuno-oncology candidates GI-101/GI-102, the allergy treatment GI-301, and the metabolic immuno-oncology candidate GI-108, most of which are in clinical stages, and it earns revenue mainly by licensing drug candidates to global pharmaceutical partners in early development stages rather than selling marketed drugs. Its partners include Simcere Pharmaceutical in China, Yuhan Corporation for GI-301 outside Japan, and MSD for joint clinical work, with clinical trials conducted in Korea, the United States, and Australia.
Written by AI from the company's latest annual report.
- Korean name
- 지아이이노베이션
- Sector
- Biotech & Pharma
- CEO
- 장명호, 홍준호(각자대표이사)
- Founded
- Jul 2017
- Listed
- Mar 2023
- Listed shares
- 64,516,006
- Fiscal year ends
- Month 12
- Website
- www.gi-innovation.com/kr/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Major management matter relevant to investorsOct 23, 2026
- 5%+ holding reportOct 7, 2026
- Amended: Major management matter relevant to investorsOct 1, 2026
- 5%+ holding reportSep 4, 2026
- Major management matter relevant to investorsAug 21, 2026
Titles in Korean until English translations are added.
Also known as: GI Innovation / 지아이이노베이션 / 358570 / KRX:358570
Source: KRX statistical information